T1	Participants 226 261	difficult in pancreatic cancer (PC)
T2	Participants 412 445	confirmation of treatment failure
T3	Participants 532 614	until progression of disease in 90 patients with PC undergoing gemcitabine therapy
T4	Participants 616 654	In Group A (January 2006-October 2007)
T5	Participants 813 852	In Group B (November 2007-October 2008)
T6	Participants 1082 1125	In Group A (CA19-9, n = 38; SPan-1, n = 36)
T7	Participants 1283 1327	In Group B (CA19-9, n = 18; SPan-1, n = 17),
